BRBettina Riedel

Bettina Riedel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bettina Riedel has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Emmet McCormack

    Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Centre for Pharmacy, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; K.G. Jebsen Center for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway; Department of Hematology, Haukeland University Hospital, Jonas Lies vei 83, 5021, Bergen, Norway

    2 shared publications
  • Jan Schjøtt

    Department of Heart Disease Haukeland University Hospital Bergen Norway

    2 shared publications
  • Spiros Kotopoulis

    National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Jonas Lies vei 83, 5021, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Jonas Lies vei 91 B, 5021, Bergen, Norway

    2 shared publications
  • Bjørn Tore Gjertsen

    Haukeland University Hospital Bergen Norway

    1 shared publication
  • Cato Innerdal

    Public Health Officer Molde, Norway

    1 shared publication
  • Elisa Thodesen Murvold

    KinN Therapeutics AS, Bergen 5021, Norway

    1 shared publication

Latest Publications

  • Open Access

    Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys

    by Oystein Eikrem, Spiros Kotopoulis, Mihaela Popa, Mireia Mayoral Safont, Kjell Ove Fossan, Sabine Leh, Lea Landolt, Janka Babickova, Oddrun Anita Gudbrandsen, Odd Helge Gilja, et al.

    The use of ultrasound and microbubble-enhanced drug delivery, commonly referred to as sonoporation, has reached numerous clinical trials and has shown favourable results. Nevertheless, the microbubbles and acoustic path also pass through healthy tissues. To date, the majority of studies have focused on the impact to diseased tissues and rarely evaluated the impact on healthy and collateral tissue. The aim of this study was to test the effect and feasibility of low-intensity sonoporation on healthy kidneys in a mouse model. In our work here, we used a clinical diagnostic ultrasound system (GE Vivid E9) with a C1-5 ultrasound transducer combined with a software modification for 20-µs-long pulses to induce the ultrasound-guided drug delivery of doxorubicin (DOX) in mice kidneys in combination with SonoVue® and Sonazoid™ microbubbles. The acoustic output settings were within the commonly used diagnostic ranges. Sonoporation with SonoVue® resulted in a significant decrease in weight vs. DOX alone (p = 0.0004) in the first nine days, whilst all other comparisons were not significant. Ultrasound alone resulted in a 381% increase in DOX uptake vs. DOX alone (p = 0.0004), whilst SonoVue® (p = 0.0001) and Sonazoid™ (p < 0.0001) further increased the uptake nine days after treatment (419% and 493%, respectively). No long-standing damage was observed in the kidneys via histology. In future sonoporation and drug uptake studies, we therefore suggest including an “ultrasound alone” group to verify the actual contribution of the individual components of the procedure on the drug uptake and to perform collateral damage studies to ensure there is no negative impact of low-intensity sonoporation on healthy tissues.


  • Open Access

    Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells

    by Tormod Bjånes, Spiros Kotopoulis, Elisa Thodesen Murvold, Tina Kamčeva, Bjørn Tore Gjertsen, Odd Helge Gilja, Jan Schjøtt, Bettina Riedel, Emmet McCormack

    Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer death worldwide. Poor drug delivery to tumours is thought to limit chemotherapeutic treatment efficacy. Sonoporation combines ultrasound (US) and microbubbles to increase the permeability of cell membranes. We assessed gemcitabine uptake combined with sonoporation in vitro in three PDAC cell lines (BxPC-3, MIA PaCa-2 and PANC-1). Cells were cultured in hypoxic bioreactors, while gemcitabine incubation ± sonoporation was conducted in cells with operational or inhibited nucleoside membrane transporters. Intracellular active metabolite (dFdCTP), extracellular gemcitabine, and inactive metabolite (dFdU) concentrations were measured with liquid chromatography tandem mass spectrometry. Sonoporation with increasing US intensities resulted in decreasing extracellular gemcitabine concentrations in all three cell lines with inhibited membrane transporters. In cells with inhibited membrane transporters, without sonoporation, dFdCTP concentrations were reduced down to 10% of baseline. Sonoporation partially restored gemcitabine uptake in these cells, as indicated by a moderate increase in dFdCTP concentrations (up to 37% of baseline) in MIA PaCa-2 and PANC-1. In BxPC-3, gemcitabine was effectively inactivated to dFdU, which might represent a protective mechanism against dFdCTP accumulation in these cells. Intracellular dFdCTP concentrations did not change significantly following sonoporation in any of the cell lines with operational membrane transporters, indicating that the gemcitabine activation pathway may have been saturated with the drug. Sonoporation allowed a moderate increase in gemcitabine transmembrane uptake in all three cell lines, but pre-existing nucleoside transporters were the major determinants of gemcitabine uptake and retention.


  • Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids

    by Maren Cecilie Strand, Jørg Mørland, Lars Slørdal, Bettina Riedel, Cato Innerdal, Trond Aamo, Grete Mathisrud, Vigdis Vindenes